Fatty liver breakthrough? scientists target gene switches

NCT ID NCT06332677

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how certain gene regulators, called SUV420H1/2, affect fatty liver disease (NAFLD). Researchers will analyze data from 260 people and use lab models to see if blocking these genes could reduce liver fat and damage. The goal is to find a new way to treat this common liver condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this research could point toward a new treatment for fatty liver disease by targeting specific genes.

What could go wrong

This is an early-stage observational and lab study, not a clinical treatment trial. Results may not lead to a usable therapy for years, if at all.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NAFLD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - Istituto di Ricovero e Cura a Carattere Scientifico di natura pubblica

    RECRUITING

    Milan, 20122, Italy

    Contact Phone: •••-•••-•••• Email: •••••@•••••